Compare CLPS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | EVAX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | Hong Kong | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 25.9M |
| IPO Year | 2017 | 2020 |
| Metric | CLPS | EVAX |
|---|---|---|
| Price | $1.06 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 18.0K | ★ 211.1K |
| Earning Date | 03-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $2.72 |
| 52 Week High | $1.88 | $12.15 |
| Indicator | CLPS | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 56.30 |
| Support Level | $0.84 | $2.91 |
| Resistance Level | $1.12 | $3.62 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 84.24 | 51.85 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.